Arkolith/Insider Trading/SGMT/Form 4

Kemble George

DirectorSagimet Biosciences Inc. (SGMT) · full profile →Form 4 · filed Jul 20, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
16
0 non-derivative · 16 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 18, 2023Grant(A)7K—$07K
Jul 18, 2023Grant(A)21K—$021K
Jul 18, 2023Disposed to issuer(D)21K—$00
Jul 18, 2023Grant(A)526K—$0526K
Jul 18, 2023Disposed to issuer(D)526K—$00
Jul 18, 2023Grant(A)46K—$046K
Jul 18, 2023Disposed to issuer(D)46K—$00
Jul 18, 2023Disposed to issuer(D)6K—$00
Jul 18, 2023Grant(A)6K—$06K
Jul 18, 2023Disposed to issuer(D)3K—$00
Jul 18, 2023Grant(A)3K—$03K
Jul 18, 2023Disposed to issuer(D)7K—$00
Jul 18, 2023Disposed to issuer(D)26K—$00
Jul 18, 2023Grant(A)26K—$026K
Jul 18, 2023Disposed to issuer(D)368K—$00
Jul 18, 2023Grant(A)368K—$0368K

Transaction Codes

A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-23-082726) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML